id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-282507-swxs5pr1	Lacaille-Dubois, Marie-Aleth	Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review	2019-07-31		.txt	text/plain	8445	355	43	The second part of the review is related to phase I-III clinical trials of QS-21, mostly formulated in ASs, to evaluate efficacy, immunogenicity and safety of adjuvanted prophylactic vaccines against infectious diseases, e.g. malaria, herpes zoster, tuberculosis, AIDS and therapeutic vaccines against cancer and Alzheimer's disease. They can act on one or more of the following targets to increase response to Ags: (1) sustaining release at the injection site (depot effect), (2) transient secretion of cytokines and chemokines, (3) recruitement of various immune cells (neutrophils, monocytes, eosinophils, macrophages and Dendritic Cells (DCs) at the injection site leading to a local immune-competent environment, (4) expression by the recruited APCs of various Pathogen Recognition Receptors (PRRs) both on their surface (Toll-like receptors, TLRs, C-type lectin receptors, CLRs), and intracellularly (Nucleotide Oligomerization Domain (NOD)-like receptors (NLRs) and Retinoic Inducible Gene-1 (RIG)-like receptors (RLRs)), which are recognized and/or activated by adjuvants, (5) maturation and activation of recruited APCs which up-regulate the expression of Major Histocompatibility Complex (MHC)-I and/or MHC-II and activation of co-stimulatory signals CD40, CD80/86, (6) increased capacity of APCs for Ag processing and presentation by MHC, (7) migration of the mature APCs to the draining lymph nodes (dLNs) to interact with Ag-specific B or T lymphocytes (through receptor-ligand interactions, MHC-T cell receptor (MHC-TCR), CD40-CD40L, CD80/86-CD28) which are activated to produce potent Ab-secreting B cells and/or effector CD8 + T cell responses (Awate et al., 2013) .	./cache/cord-282507-swxs5pr1.txt	./txt/cord-282507-swxs5pr1.txt